Drug development in dementia

Emma L. Cunningham*, Anthony P. Passmore

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

5 Citations (Scopus)

Abstract

Dementia is a progressive, irreversible decline in cognition that, by definition, impacts on a patient's pre-existing level of functioning. The clinical syndrome of dementia has several aetiologies of which Alzheimer's disease (AD) is the most common. Drug development in AD is based on evolving pathophysiological theory. Disease modifying approaches include the targeting of amyloid processing, aggregation of tau, insulin signalling, neuroinflammation and neurotransmitter dysfunction, with efforts thus far yielding abandoned hopes and ongoing promise. Reflecting its dominance on the pathophysiological stage the amyloid cascade is central to many of the emerging drug therapies. The long preclinical phase of the disease requires robust biomarker means of identifying those at risk if timely intervention is to be possible.

Original languageEnglish
Pages (from-to)260-266
Number of pages7
JournalMaturitas
Volume76
Issue number3
DOIs
Publication statusPublished - 01 Nov 2013

Keywords

  • Alzheimer's disease
  • Dementia
  • Drugs
  • Therapeutic developments

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Obstetrics and Gynaecology

Fingerprint

Dive into the research topics of 'Drug development in dementia'. Together they form a unique fingerprint.

Cite this